Allan J W Lui

8PUBLICATIONS
43CO-AUTHORS
Molecular targetsChemical engineering designApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 11, 2024
Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and MDM2 Amplification.

Arielle Elkrief, Igor Odintsov, Roger S Smith

|Aug 09, 2024
HER2 Antibody-Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor.

Tom Zhang, Christopher A Febres-Aldana, Zebing Liu

|Oct 09, 2023
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.

Isao Miyazaki, Igor Odintsov, Keiji Ishida

|Sep 24, 2023
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.

Isao Miyazaki, Igor Odintsov, Keiji Ishida

|Feb 09, 2022
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.

Alison M Schram, Igor Odintsov, Madelyn Espinosa-Cotton

|Jan 25, 2022
CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma.

Igor Odintsov, Michael V Ortiz, Inna Khodos

Pageof 2

Frequent Collaborators

4 joint publications

Elisa de Stanchina

3 joint publications

Romel Somwar

3 joint publications

Morana Vojnic

2 joint publications

Monika A Davare